Drug intelligence / Profile preview

PTX-104

Development stage: Unknown
Modality: Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

PTX-104 is an investigational therapeutic mRNA cancer vaccine attributed to Providence Therapeutics. Drug databases report preclinical development for neoplasms, but do not identify its encoded antigens or provide an asset-specific mechanism. ([synapse.patsnap.com](https://synapse.patsnap.com/drug/274718a419ea493b9730f0a9beaa2d84))

Other names: PTX 104PTX104PTX-104

Beyond the preview

Go deeper on PTX-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTX-104.